- call +1-201-465-4211
- email sales@mrinsights.biz
Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals.
Scope of the Report:
This report focuses on the Gaucher Disease in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Sales of Gaucher disease therapeutics will rise gradually from 1500.48 million in 2016 to 2045.70 million by 2021 across worldwide, at a Compound Annual Growth Rate (CAGR) of 5.30%. And the market dominance of the USA is set to continue during the forecast period, with the country commanding approximately 54.71% of the Gaucher disease treatment by 2021.
The technical barriers of Gaucher disease industry are existed apparently. The key technology and higher level products are in the hand of the global leading enterprise like Sanofi, Shire, Actelion Pharma, Pfizer, etc.
There are 5 FDA-approved drugs for type I Gaucher’s disease, Cerezyme (imiglucerase) in 1993, Cerdelga (eliglustat) in 2014, VPRIV (velaglucerase alfa) for 2010, Elelyso (taliglucerase alfa) for 2012, and Zavesca (miglustat) in 2003. One KFDA-approved drugs for type I Gaucher’s disease Abcertin® FOR 2012.
The worldwide market for Gaucher Disease is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Sanofi
Shire
Actelion Pharma
Pfizer
ISU Pharm
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Enzyme Replacement Therapy
Substrate Reduction Therapy
Market Segment by Applications, can be divided into
Non-Neuronopathic Gaucher Disease
Neuronopathic Gaucher Disease
There are 15 Chapters to deeply display the global Gaucher Disease market.
Chapter 1, to describe Gaucher Disease Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Gaucher Disease, with sales, revenue, and price of Gaucher Disease, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Gaucher Disease, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Gaucher Disease market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Gaucher Disease sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Gaucher Disease Introduction
1.2 Market Analysis by Type
1.2.1 Enzyme Replacement Therapy
1.2.2 Substrate Reduction Therapy
1.3 Market Analysis by Applications
1.3.1 Non-Neuronopathic Gaucher Disease
1.3.2 Neuronopathic Gaucher Disease
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Business Overview
2.1.2 Gaucher Disease Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Sanofi Gaucher Disease Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Shire
2.2.1 Business Overview
2.2.2 Gaucher Disease Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Shire Gaucher Disease Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Actelion Pharma
2.3.1 Business Overview
2.3.2 Gaucher Disease Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Actelion Pharma Gaucher Disease Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Gaucher Disease Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Gaucher Disease Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 ISU Pharm
2.5.1 Business Overview
2.5.2 Gaucher Disease Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ISU Pharm Gaucher Disease Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gaucher Disease Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Gaucher Disease Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Gaucher Disease Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Gaucher Disease Manufacturer Market Share in 2017
3.3.2 Top 6 Gaucher Disease Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Gaucher Disease Market Analysis by Regions
4.1 Global Gaucher Disease Sales, Revenue and Market Share by Regions
4.1.1 Global Gaucher Disease Sales and Market Share by Regions (2013-2018)
4.1.2 Global Gaucher Disease Revenue and Market Share by Regions (2013-2018)
4.2 North America Gaucher Disease Sales and Growth Rate (2013-2018)
4.3 Europe Gaucher Disease Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Gaucher Disease Sales and Growth Rate (2013-2018)
4.5 South America Gaucher Disease Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Gaucher Disease Sales and Growth Rate (2013-2018)
5 North America Gaucher Disease by Countries
5.1 North America Gaucher Disease Sales, Revenue and Market Share by Countries
5.1.1 North America Gaucher Disease Sales and Market Share by Countries (2013-2018)
5.1.2 North America Gaucher Disease Revenue and Market Share by Countries (2013-2018)
5.2 United States Gaucher Disease Sales and Growth Rate (2013-2018)
5.3 Canada Gaucher Disease Sales and Growth Rate (2013-2018)
5.4 Mexico Gaucher Disease Sales and Growth Rate (2013-2018)
6 Europe Gaucher Disease by Countries
6.1 Europe Gaucher Disease Sales, Revenue and Market Share by Countries
6.1.1 Europe Gaucher Disease Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Gaucher Disease Revenue and Market Share by Countries (2013-2018)
6.2 Germany Gaucher Disease Sales and Growth Rate (2013-2018)
6.3 UK Gaucher Disease Sales and Growth Rate (2013-2018)
6.4 France Gaucher Disease Sales and Growth Rate (2013-2018)
6.5 Russia Gaucher Disease Sales and Growth Rate (2013-2018)
6.6 Italy Gaucher Disease Sales and Growth Rate (2013-2018)
7 Asia-Pacific Gaucher Disease by Countries
7.1 Asia-Pacific Gaucher Disease Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Gaucher Disease Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Gaucher Disease Revenue and Market Share by Countries (2013-2018)
7.2 China Gaucher Disease Sales and Growth Rate (2013-2018)
7.3 Japan Gaucher Disease Sales and Growth Rate (2013-2018)
7.4 Korea Gaucher Disease Sales and Growth Rate (2013-2018)
7.5 India Gaucher Disease Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Gaucher Disease Sales and Growth Rate (2013-2018)
8 South America Gaucher Disease by Countries
8.1 South America Gaucher Disease Sales, Revenue and Market Share by Countries
8.1.1 South America Gaucher Disease Sales and Market Share by Countries (2013-2018)
8.1.2 South America Gaucher Disease Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Gaucher Disease Sales and Growth Rate (2013-2018)
8.3 Argentina Gaucher Disease Sales and Growth Rate (2013-2018)
8.4 Colombia Gaucher Disease Sales and Growth Rate (2013-2018)
9 Middle East and Africa Gaucher Disease by Countries
9.1 Middle East and Africa Gaucher Disease Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Gaucher Disease Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Gaucher Disease Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Gaucher Disease Sales and Growth Rate (2013-2018)
9.3 UAE Gaucher Disease Sales and Growth Rate (2013-2018)
9.4 Egypt Gaucher Disease Sales and Growth Rate (2013-2018)
9.5 Nigeria Gaucher Disease Sales and Growth Rate (2013-2018)
9.6 South Africa Gaucher Disease Sales and Growth Rate (2013-2018)
10 Global Gaucher Disease Market Segment by Type
10.1 Global Gaucher Disease Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Gaucher Disease Sales and Market Share by Type (2013-2018)
10.1.2 Global Gaucher Disease Revenue and Market Share by Type (2013-2018)
10.2 Enzyme Replacement Therapy Sales Growth and Price
10.2.1 Global Enzyme Replacement Therapy Sales Growth (2013-2018)
10.2.2 Global Enzyme Replacement Therapy Price (2013-2018)
10.3 Substrate Reduction Therapy Sales Growth and Price
10.3.1 Global Substrate Reduction Therapy Sales Growth (2013-2018)
10.3.2 Global Substrate Reduction Therapy Price (2013-2018)
11 Global Gaucher Disease Market Segment by Application
11.1 Global Gaucher Disease Sales Market Share by Application (2013-2018)
11.2 Non-Neuronopathic Gaucher Disease Sales Growth (2013-2018)
11.3 Neuronopathic Gaucher Disease Sales Growth (2013-2018)
12 Gaucher Disease Market Forecast (2018-2023)
12.1 Global Gaucher Disease Sales, Revenue and Growth Rate (2018-2023)
12.2 Gaucher Disease Market Forecast by Regions (2018-2023)
12.2.1 North America Gaucher Disease Market Forecast (2018-2023)
12.2.2 Europe Gaucher Disease Market Forecast (2018-2023)
12.2.3 Asia-Pacific Gaucher Disease Market Forecast (2018-2023)
12.2.4 South America Gaucher Disease Market Forecast (2018-2023)
12.2.5 Middle East and Africa Gaucher Disease Market Forecast (2018-2023)
12.3 Gaucher Disease Market Forecast by Type (2018-2023)
12.3.1 Global Gaucher Disease Sales Forecast by Type (2018-2023)
12.3.2 Global Gaucher Disease Market Share Forecast by Type (2018-2023)
12.4 Gaucher Disease Market Forecast by Application (2018-2023)
12.4.1 Global Gaucher Disease Sales Forecast by Application (2018-2023)
12.4.2 Global Gaucher Disease Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Gaucher Disease Picture
Table Product Specifications of Gaucher Disease
Figure Global Sales Market Share of Gaucher Disease by Types in 2017
Table Gauch
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
